Plasma and synovial fluid concentrations and cartilage toxicity of bupivacaine following intra-articular administration of a liposomal formulation to horses.
Authors: Knych H K, Mama K R, Moore C E, Hill A E, McKEMIE D S
Journal: Equine veterinary journal
Summary
# Editorial Summary Intra-articular local anaesthetics offer valuable post-operative pain relief in equine practice, yet concerns persist regarding their chondrotoxic potential, with existing evidence yielding contradictory results. Researchers administered liposomal bupivacaine into the metacarpophalangeal joints of anaesthetised horses and measured drug concentrations in plasma and synovial fluid over 72 hours whilst simultaneously assessing cartilage damage through established toxicity markers and histological examination. Peak synovial bupivacaine concentrations remained considerably higher than plasma levels, with therapeutic drug presence sustained throughout the 72-hour observation period, though the formulation did not induce measurable chondrocyte damage or cartilage degradation under the conditions tested. These findings suggest liposomal bupivacaine could extend analgesia substantially beyond conventional formulations without compromising joint integrity; however, the absence of long-term follow-up data and the controlled nature of the study warrant caution before widespread adoption, particularly regarding repeated dosing protocols or use in joints already compromised by osteoarthritis or infection. For practitioners considering this technology, the extended analgesic window represents a genuine advance in post-operative management, yet further investigation into real-world applications and potential for misuse as a performance-enhancing agent remains warranted.
Read the full abstract on PubMed
Practical Takeaways
- •Liposomal bupivacaine shows promise for extended post-operative joint analgesia in horses, but safety profile requires evaluation before clinical adoption
- •Until equine-specific safety data is available, practitioners should exercise caution with this formulation and monitor for signs of cartilage damage
- •Further research needed to establish dosing, duration of effect, and chondrotoxicity potential in equine joints before considering routine use
Key Findings
- •Liposomal bupivacaine formulation is used in people and dogs to provide up to 72 hours of analgesia via intra- and peri-articular administration
- •Effects of local anaesthetics on equine chondrocytes are mixed, with some studies reporting chondrodestruction while others report no adverse effects
- •Potential for chondrotoxicity, side effects, and abuse (long-term analgesic effects) of liposomal bupivacaine has not been evaluated in horses